Neuronetics Target of Unusually Large Options Trading (NASDAQ:STIM)

Neuronetics, Inc. (NASDAQ:STIM) was the recipient of unusually large options trading on Thursday. Investors purchased 5,519 call options on the stock. This is an increase of approximately 905% compared to the typical volume of 549 call options.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the business. David J Yvars Group lifted its stake in shares of Neuronetics by 22.1% during the 4th quarter. David J Yvars Group now owns 31,230 shares of the company’s stock worth $43,000 after acquiring an additional 5,650 shares during the last quarter. National Bank of Canada FI grew its position in Neuronetics by 27.5% in the 3rd quarter. National Bank of Canada FI now owns 31,880 shares of the company’s stock valued at $87,000 after acquiring an additional 6,880 shares during the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new stake in Neuronetics in the second quarter worth $34,000. AdvisorShares Investments LLC lifted its position in shares of Neuronetics by 8.3% during the second quarter. AdvisorShares Investments LLC now owns 130,534 shares of the company’s stock worth $456,000 after purchasing an additional 10,000 shares during the last quarter. Finally, Squarepoint Ops LLC boosted its stake in shares of Neuronetics by 20.0% during the third quarter. Squarepoint Ops LLC now owns 62,458 shares of the company’s stock valued at $171,000 after purchasing an additional 10,423 shares during the period. Institutional investors own 53.59% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on STIM. Weiss Ratings restated a “sell (e+)” rating on shares of Neuronetics in a report on Wednesday, October 8th. Wall Street Zen raised Neuronetics from a “sell” rating to a “hold” rating in a research note on Saturday, December 6th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Neuronetics has a consensus rating of “Hold” and a consensus target price of $7.00.

Neuronetics Price Performance

NASDAQ:STIM opened at $2.20 on Friday. The firm has a market capitalization of $150.68 million, a price-to-earnings ratio of -2.68 and a beta of 0.66. The company has a debt-to-equity ratio of 2.09, a current ratio of 2.24 and a quick ratio of 2.09. The business has a 50 day simple moving average of $1.56 and a 200-day simple moving average of $2.68. Neuronetics has a 1 year low of $1.25 and a 1 year high of $5.92.

Neuronetics (NASDAQ:STIM) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.02). The company had revenue of $37.30 million for the quarter, compared to analysts’ expectations of $37.85 million. Neuronetics had a negative net margin of 33.88% and a negative return on equity of 131.15%. Equities analysts forecast that Neuronetics will post -1.13 EPS for the current year.

Neuronetics Company Profile

Neuronetics, Inc is a commercial‐stage medical technology company that develops and markets non-invasive neuromodulation therapies for psychiatric and neurological disorders. The company’s flagship product, the NeuroStar Advanced Therapy System, uses repetitive transcranial magnetic stimulation (rTMS) to deliver targeted magnetic pulses to areas of the brain implicated in major depressive disorder (MDD). NeuroStar Advanced Therapy has received U.S. Food and Drug Administration clearance for the treatment of adults with treatment-resistant depression and is supported by a growing body of clinical evidence demonstrating its safety and efficacy.

Founded in 2003 and headquartered in Malvern, Pennsylvania, Neuronetics focuses on advancing clinical care through innovation in neurostimulation.